Treating Climacteric Symptoms With a Complex Homeopathic Remedy
Launched by HEIDELBERG UNIVERSITY · Sep 8, 2005
Trial Information
Current as of May 06, 2025
Completed
Keywords
ClinConnect Summary
Complementary treatments for climacteric symptoms are used by many women although their efficacy and safety is mostly unproven.
The use of the complex homeopathic remedy Ovaria comp. for the relief of climacteric symptoms will be examined in this three-armed intervention trial and measured with the menopause rating scale II before and after each study phase of 12 weeks. Participants will receive the verum during two treatment phases of 12 weeks and the placebo during one treatment phase of 12 weeks in different sequences and are stratified for post- and perimenopausal status.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Climacteric symptoms\>=3 Points in Menopause Rating Scale (MRS) II
- • Communication possible
- Exclusion Criteria:
- • Hormone replacement therapy within 2 weeks prior to study inclusion
- • Other complementary treatments 7 days before and during the study
- • Climacteric symptoms caused by operation, chemotherapy or hormonal therapy of cancer
- • Allergy to components of the remedy, especially bee poison
About Heidelberg University
Heidelberg University, a prestigious institution located in Germany, is renowned for its commitment to advancing medical research and clinical innovation. With a strong emphasis on interdisciplinary collaboration, the university fosters a dynamic environment for conducting clinical trials that aim to enhance patient care and improve health outcomes. Leveraging cutting-edge technology and a robust network of healthcare professionals, Heidelberg University is dedicated to exploring novel therapeutic approaches and contributing to the global medical community through rigorous scientific inquiry and ethical research practices.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Heidelberg, Baden Württemberg, Germany
Patients applied
Trial Officials
Cornelia U von Hagens, MD
Principal Investigator
Heidelberg University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials